Search results
Here’s Why Supernus Pharmaceuticals (SUPN) Outperformed in Q3
Insider Monkey via Yahoo Finance· 1 year agoScout Investments, an affiliate of Carillon Tower Advisers, an investment management company,...
Supernus Pharmaceuticals (SUPN): A Hidden Gem in the Market? A Comprehensive Analysis of Its ...
GuruFocus.com via Yahoo Finance· 9 months agoSupernus Pharmaceuticals Inc (NASDAQ:SUPN) has recently seen a daily gain of 2.28%, despite a...
Supernus Pharmaceuticals Inc (SUPN) Reports Robust Growth in Key Products for Full Year 2023
GuruFocus.com via Yahoo Finance· 4 months agoNet Sales Growth: Qelbree's net sales surged by 129% to $140.2 million in 2023, while GOCOVRI...
Supernus Pharmaceuticals (SUPN) Q2 Earnings Lag Estimates
Zacks via Yahoo Finance· 2 years agoSupernus (SUPN) delivered earnings and revenue surprises of -53.33% and 2.23%, respectively, for the...
Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Stock Is Rallying But Financials Look Ambiguous: Will...
Simply Wall St. via Yahoo Finance· 2 years agoSupernus Pharmaceuticals (NASDAQ:SUPN) has had a great run on the share market with its stock up by...
Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders have earned a 8.7% CAGR over the last three...
Simply Wall St. via Yahoo Finance· 6 months agoIt hasn't been the best quarter for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) shareholders, since...
Supernus Pharmaceuticals (SUPN) Earnings Expected to Grow: Should You Buy?
Zacks via Yahoo Finance· 1 year agoSupernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely...
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Has Fared Decently But Fundamentals Look Uncertain:...
Simply Wall St. via Yahoo Finance· 5 months agoMost readers would already know that Supernus Pharmaceuticals' (NASDAQ:SUPN) stock increased by 9.4%...
Ahead of Supernus (SUPN) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Zacks via Yahoo Finance· 4 months agoBesides Wall Street's top -and-bottom-line estimates for Supernus (SUPN), review projections for...
The past five years for Supernus Pharmaceuticals (NASDAQ:SUPN) investors has not been profitable
Simply Wall St. via Yahoo Finance· 2 years agoWhile not a mind-blowing move, it is good to see that the Supernus Pharmaceuticals, Inc....